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563 Abstract
64 Objective: To evaluate serum estradiol (E2) concentrations during use of 90-day contraceptive 
65 vaginal rings releasing E2 75, 100, or 200 mcg/day and segesterone acetate (SA) 200 mcg/day to 
66 identify a dose that avoids hypoestrogenism. 
67 Study Design: We conducted a multicenter dose-finding study in healthy, reproductive-aged 
68 women with regular cycles with sequential enrollment to increasing E2 dose groups. We 
69 evaluated serum E2 concentrations twice weekly for the primary outcome of median E2 
70 concentrations throughout initial 30-day use (target ≥40 pg/mL). In an optional 2-cycle extension 
71 substudy, we randomized participants to 2- or 4-day ring-free intervals per 30-day cycle to 
72 evaluate bleeding and spotting based on daily diary information.
73 Results: Sixty-five participants enrolled in E2 75 (n=22), 100 (n=21), and 200 (n=22) mcg/day 
74 groups; 35 participated in the substudy. Median serum E2 concentrations in 75 and 100 mcg/day 
75 groups were <40 pg/mL. In the 200 mcg/day group, median E2 concentrations peaked on days 4-
76 5 of CVR use at 194 pg/mL (range 114-312 pg/mL) and remained >40 pg/mL throughout 30 
77 days; E2 concentrations were 37 pg/mL (range 28-62 pg/mL) on days 88-90 (n=11). Among the 
78 E2 200 mcg/day substudy participants, all had withdrawal bleeding following ring removal. The 
79 2-day ring-free interval group reported zero median unscheduled bleeding and two (range 0-16) 
80 and three (range 0-19) unscheduled spotting days in extension cycles 1 and 2, respectively. The 
81 4-day ring-free interval group reported zero median unscheduled bleeding or spotting days. 
82 Conclusions: Estradiol concentrations with rings releasing E2 200 mcg/day and SA 200 mcg/day 
83 avoid hypoestrogenism over 30-day use.  
84
685 Implications: A 90-day contraceptive vaginal ring releasing estradiol 200 mcg/day and 
86 segesterone acetate 200 mcg/day achieves estradiol concentrations that should avoid 
87 hypoestrogenism and effectively suppresses ovulation.
88
89 Key words: segesterone acetate, Nestorone®, estradiol, clinical trial, contraception, vaginal ring
90
791 1.0 Introduction
92 Segesterone acetate (SA, also known as Nestorone®) is a progestin that has low 
93 bioavailability with oral administration, but demonstrates potent activity via vaginal, 
94 transdermal, or subdermal routes [1]. While SA-only vaginal rings releasing up to 100 mcg/day 
95 demonstrated effective ovulation inhibition with continuous use [2], follicular development 
96 persisted, which could result in ovulation with breaks in usage (e.g. a 7-day ring-free interval). In 
97 addition, concerns regarding unfavorable bleeding profiles led to addition of estrogen during ring 
98 development. Subsequently, a contraceptive vaginal system releasing ethinyl estradiol 13 
99 mcg/day and SA 150 mcg/day for cyclic use over one year has recently received FDA approval, 
100 offering women a user-controlled, combined hormonal method with a longer duration of action 
101 compared with other available combined hormonal methods [3-5]. 
102 Contraceptive products containing ethinyl estradiol may increase the risk of venous 
103 thromboembolism, especially among obese women [6-8]. This risk may be increased even when 
104 ethinyl estradiol is delivered vaginally due to systemic absorption and significant second-pass 
105 hepatic metabolism [9-12]. Alternatively, a contraceptive ring delivering 17-beta estradiol (E2) 
106 with a progestin should not increase thromboembolic risk as ethinyl estradiol does [13]. This 
107 product may offer safety advantages to users [14], particularly to those who are obese. 
108 As higher doses of SA may lead to hypoestrogenism by preventing ovarian 
109 folliculogenesis and estrogen production [2], an adequate E2 replacement dose in the vaginal 
110 delivery device is required. A previous Phase 2a dose-finding study evaluated serum E2 
111 concentrations with a 90-day vaginal ring releasing E2 at 10, 20, or 40 mcg/day with SA 200 
112 mcg/day. These rings included a higher SA dose to ensure complete ovarian suppression, 
113 including in obese women, given the potentially less gonadotropic effect from E2 as opposed to 
8114 ethinyl estradiol [14]. However, despite increasing E2 dose release, none of the rings achieved 
115 target serum E2 concentrations (≥40 pg/mL) [14,15]. We performed this study to evaluate serum 
116 E2 concentrations with use of a contraceptive vaginal ring (CVR) releasing higher E2 doses. In 
117 addition, we assessed bleeding patterns and side effects. 
118
119 2.0 Materials and methods
120 Seven sites of the NICHD Contraceptive Clinical Trials Network (CCTN) conducted a 
121 multicenter, open-label, dose-finding study to evaluate serum E2 concentrations over 30 days 
122 with three E2/SA CVRs releasing different E2 doses. The E2/SA CVR is comprised of a silicone 
123 elastomer; SA and E2 are mixed with elastomer and extruded to form the ring. The target 
124 diameter and cross section of the rings ranged from 56.4 to 56.6 mm and 8.10 to 8.20 mm, 
125 respectively. For this study, the Population Council manufactured three dosage formulations with 
126 a target SA release rate of 200 mcg/day combined with E2 75, 100 or 200 mcg/day. In vitro 
127 testing confirmed the rings released their targeted E2 dose through 90 days.
128 The sites for this trial included Columbia University, Eastern Virginia Medical School, 
129 Oregon Health and Science University, University of California, Davis, University of Cincinnati, 
130 University of Pennsylvania, and the University of Utah. The Chesapeake Institutional Review 
131 Board (IRB) served as the central site for protocol approval; each site’s local IRB also approved 
132 the study and individual participants signed written informed consent.
133 We used the same entry criteria as the prior dose-finding study with lower E2 doses [14]. 
134 Briefly, we enrolled healthy women 18-39 years of age with regular menstrual cycles when not 
135 using hormonal contraception, an intact uterus and both ovaries, and who were willing to abstain 
136 from non-water based vaginal lubricant use. We excluded women with known hypersensitivity to 
9137 progestins, estrogen, or silicone rubber, contraindication to combined estrogen-progestin 
138 contraceptive use, injectable contraceptive use within nine months prior to enrollment or without 
139 a spontaneous menses since last injection, history of toxic shock syndrome, anatomical 
140 abnormality that precluded use of a vaginal ring (e.g. cystocele), severe constipation, or body 
141 mass index ≥ 35 kg/m2. We also excluded women using isotretinoin, sex steroid hormonal 
142 medications, vaginal treatment for other illnesses, or CYP3A4 liver enzyme-inducing or 
143 inhibiting medications. Women using hormonal contraception must have discontinued use at 
144 least seven days before enrollment. 
145 After the screening visit, participants returned during the first five days of the next 
146 spontaneous menses for enrollment. We obtained pre-treatment E2 concentrations prior to ring 
147 insertion at this visit. On-treatment visits occurred twice weekly for one month to collect blood 
148 samples for E2, SA, and progesterone measurement and to review diary cards to identify ring 
149 problems, adverse events (AEs), concomitant treatments, and any ring removals and reinsertions. 
150 We assessed spotting and bleeding using a questionnaire administered on a weekly basis. 
151 Participants had the option to complete their last visit on day 28-30 of CVR use or to enroll in a 
152 two-cycle extension substudy to evaluate bleeding patterns. We randomized those interested in 
153 the substudy to initiate either a 2- or 4-day ring-free interval at the end of each 30-day cycle and 
154 asked these participants to complete a daily bleeding diary. We followed participants after 
155 completion of CVR use until the first spontaneous menses. 
156 We planned to enroll 17-21 participants in sequential dose-escalating groups that 
157 received rings releasing E2 doses of 75, 100, or 200 mcg/day. We did not conduct a formal 
158 power and sample size calculation; enrollment targets were intended to provide measures of 
159 central tendency consistent with a proof of concept Phase 2 dose-finding study. 
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160 The primary outcome of this study was median serum E2 concentrations during 30 days 
161 of CVR use with a target of ≥40 pg/mL. While the CVRs are designed for use over 90 days, a 
162 prior trial with this ring design demonstrated that we can determine whether E2 concentrations 
163 would reach our target within the first 30-day period, allowing an earlier assessment of the 
164 suitability of these doses for further investigation [14]. Secondary outcomes included treatment 
165 compliance (based on SA concentrations  40 pg/mL), ovulation suppression, bleeding, 
166 satisfaction, side effects, and E2 concentrations in a subset of participants evaluated at 90-days of 
167 CVR use.
168 The Endocrine Technologies Core at the Oregon National Primate Research Center 
169 measured E2 and SA concentrations using liquid chromatography-tandem mass spectrometry 
170 (LC-MS/MS). For E2, the inter-assay and intra-assay precisions were 5.3% and 4.8%, 
171 respectively [16]. For SA, the inter-assay and intra-assay precisions were 14.0% and 10.7%, 
172 respectively. The lower limit of quantitation for both assays was 10 pg/mL. We defined 
173 ovulation based on laboratory criteria of two consecutive progesterone values of ≥3 ng/mL or a 
174 single progesterone concentration >10 ng/mL. We determined bleeding satisfaction with 
175 questions about bleeding and spotting in the previous seven days during the main study. For 
176 bleeding pattern analysis in the extension substudy, we based the scheduled bleeding window on 
177 criteria defined by Mishell et al [17] as any bleeding or spotting during the hormone-free interval 
178 and through the first 4 days of the next cycle. Because the hormone-free window differed 
179 between the two groups, we used an 8-day scheduled bleeding window for analyses of both 
180 groups. Unscheduled bleeding or spotting referred to any bleeding or spotting that occurred 
181 outside of this window. Safety assessments included AE collection, physical examination, and 
11
182 laboratory evaluation of hematologic, chemistry, and lipid parameters. We performed Fisher’s 
183 Exact test and Cochran-Armitage trend test using SAS software.
184
185 3.0 Results
186 We enrolled 65 women who received CVRs releasing E2 75 mcg/day (n=22), E2 100 
187 mcg/day (n=21), or E2 200 mcg/day (n=22) along with SA 200 mcg/day; 64 of these participants 
188 completed the main study. Thirty-five participants opted to continue in the extension substudy, 
189 and 33 completed the additional 60 days of CVR use (Figure 1). Participants were primarily non-
190 Hispanic white and not currently using tobacco products; about half were overweight or obese 
191 (Table 1). 
192 The median pre-treatment E2 concentration for all participants was 36.5 pg/mL (range 5-
193 110 pg/mL). Figure 2 presents the E2 concentrations of all treatment groups. Median E2 
194 concentrations remained low (<40 pg/mL) after seven days in those using CVRs releasing E2 
195 75mcg/day and E2 100 mcg/day with marginal dose response. In contrast, median E2 
196 concentrations peaked on treatment days 4 or 5 at 194 pg/mL (range 114-312 pg/mL) with E2 
197 200 mcg/day CVR use and declined to 51.5 pg/mL (range 21-109 pg/mL) at day 30. Median E2 
198 concentration was 37 pg/mL (range 28-62 pg/mL) for the 11 participants using this dose ring on 
199 treatment days 88 to 90 in the extension substudy. We identified no ovulations during study 
200 participation with any E2/SA dose product. Overall, 21 (95.5%), 20 (95.2%), and 19 (86.4%) of 
201 participants using the E2 75 mcg/day, E2 100 mcg/day, and E2 200 mcg/day rings, respectively, 
202 demonstrated full compliance with ring use as determined by SA concentrations. 
203 Bleeding and spotting occurred in all users during the first CVR week as women initiated 
204 ring use during menses. Participants using the E2 75 and 100 mcg/day CVRs reported more 
12
205 bleeding and spotting (Table 2). In contrast, only two E2 200 mcg/day CVR users reported any 
206 bleeding or spotting in weeks 2, 3, and 4 of the initial treatment cycle. Further, 20 of 43 (47%) 
207 participants using the E2 75 and 100 mcg/day CVRs considered the bleeding and spotting to be 
208 “bothersome” compared with 2 of 22 (9%) participants using the E2 200 mcg/day CVR 
209 (p=0.003). 
210 In the extension substudy, withdrawal bleeding occurred in all participants following E2 
211 200 mcg/day CVR removal as opposed to the lower dose rings (Table 3). Among E2 200 
212 mcg/day CVR users, those randomized to the 4-day ring-free interval reported a median of 0 
213 unscheduled bleeding or spotting days. Participants randomized to the 2-day ring-free interval 
214 reported a median of zero unscheduled bleeding days and a median of two (range 0-16) and three 
215 (range 0-19) unscheduled spotting days in the first and second 30-day extension cycles, 
216 respectively. Among participants randomized to the 2-day ring-free interval, more women 
217 reported spotting with increasing E2 doses (E2 75 mcg/day: 0/5; E2 100 mcg/day: 2/6; E2 200 
218 mcg/day: 4/7; p=0.04). 
219 Most participants reported at least one AE during the treatment period with the most 
220 frequently reported AEs being headaches and breast tenderness (Table 4). No early 
221 discontinuations occurred due to an AE. An investigator reported one serious AE of gastritis 
222 unrelated to the study drug. 
223
224 4.0 Discussion
225 We evaluated three E2/SA vaginal rings with different E2 release rates in this dose-
226 finding study to identify the lowest dose that would meet a predefined endpoint of median E2 
227 serum concentrations above 40 pg/mL. We found that only the CVR delivering the highest E2 
13
228 dose (E2 200 mcg/day) met the study goal. Further, this ring appeared to effectively suppress 
229 ovulation without significant side effects. Based on these findings, we chose the CVR releasing 
230 E2 200 mcg/day and SA 200 mcg/day for a Phase IIb study to evaluate contraceptive efficacy 
231 during one year of cyclic or continuous use (NCT03432416).
232 The lowest E2 dose ring (75 mcg/day) yielded E2 concentrations similar to the previous 
233 dose-finding study [14]. We found a marginal E2 dose-response with the E2 100 mcg/day dose, 
234 but the median serum levels remained below the target. Median serum E2 concentrations 
235 increased above 40 pg/mL only with E2 200 mcg/day CVR, suggesting that a threshold dose of 
236 E2 released from the CVR is needed to provide adequate sustainable E2 concentrations that 
237 could prevent hypoestrogenism resulting from suppression of the hypothalamic-pituitary-ovarian 
238 axis by SA. 
239 We acknowledge limitations with setting our study goal of achieving E2 concentrations 
240 of ≥ 40 pg/mL given long-term health implications of hypoestrogenism, including bone health. 
241 Previous studies with depot medroxyprogesterone acetate (DMPA) raised concern about peak 
242 bone mass in young users and demonstrated adverse bone mineral density changes with low 
243 serum estradiol concentrations [18-20]. With the E2 200 mcg/day ring, we found median serum 
244 E2 concentrations >50 pg/mL in the first 30 days of ring use before decreasing to 37 pg/mL at 
245 the end of the 90-day treatment period. Placement of a new ring at that point should lead to 
246 recovery of serum E2 concentrations and avoid sustained low E2 concentrations. Future 
247 proposed evaluations include measurements of E2 concentrations with sequential ring use and 
248 bone health to confirm that serum E2 concentrations with this product are sufficient for avoiding 
249 hypoestrogenism.
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250 Contraceptives using E2 rather than ethinyl estradiol have generally resulted in bleeding 
251 patterns with high rates of unscheduled bleeding. The first E2-containing pill (estradiol valerate 
252 and dienogest) featured a complex quadriphasic regimen to improve cycle control [21]. With the 
253 second combined hormonal pill containing E2 and nomegestrol acetate in a 24/4 regimen, 
254 women experienced a decrease in unscheduled bleeding over time and increase in amenorrhea 
255 with continued use [22]. Bleeding patterns with investigational CVRs containing E2 and various 
256 doses of nomegestrol or etonogestrel showed that unscheduled bleeding decreases over time with 
257 all rings; however, bleeding predictability may not compare with ethinyl estradiol-based 
258 contraceptives [23, 24]. In this study, we evaluated CVRs containing three doses of E2 combined 
259 with a progestin dose that effectively suppresses follicular development and endogenous ovarian 
260 estrogen synthesis. Women using the E2 200 mcg/day CVR reported fewer bothersome 
261 unscheduled bleeding or spotting days in the first 30 days of use compared with women using 
262 lower E2 dose CVRs. This initial experience may be a critical time for determining acceptability 
263 of the method for new users. Additionally, cyclic ring-free intervals appeared to result in 
264 predictable withdrawal bleeds for most participants. Among participants using the E2 200 
265 mcg/day CVR, the only dose that met target serum E2 concentrations, less unscheduled bleeding 
266 or spotting occurred in the group assigned to a 4-day ring-free interval group compared to the 
267 group assigned to a 2-day ring-free interval. However, the small number of participants in the 
268 extension substudy and the short data collection period (i.e. two 30-day cycles) limit our ability 
269 to predict the bleeding patterns in a larger group of women. 
270 We have determined that the CVR releasing E2 200 mcg/day and SA 200 mcg/day is 
271 capable of achieving adequate E2 concentrations to avoid hypoestrogenism. Additional 
15
272 evaluations are currently underway to determine contraceptive efficacy, bleeding patterns, safety, 
273 and acceptability of this product.  
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Table 1. Participant characteristics in a dose-finding study of contraceptive vaginal ring releasing 
estradiol 75 mcg, 100 mcg, or 200 mcg per day and segesterone acetate 200 mcg per day
E2 75 mcg/day and
SA 200 mcg/day
n=22
E2 100 mcg/day and
SA 200 mcg/day
n=21
E2 200 mcg/day and
SA 200 mcg/day
n=22
Age (years) 27.0 ± 5.4 27.8 ± 6.6 30.0 ± 5.4
Non-Hispanic ethnicity 19 (86.4) 20 (95.2) 21 (95.5)
Race
White
Black
Other
13 (59.1)
6 (27.3)
3 (13.6)
14 (66.7)
3 (14.3)
4 (19.0)
15 (68.2)
5 (22.7)
2 (9.1)
Gravidity
0
1
2 or more
14 (66.7)
3 (14.3)
4 (18.2)
11 (52.4)
2 (9.5)
8 (38.1)
13 (59.1)
4 (18.2)
5 (22.7)
Parity
0
1
2 or more
16 (72.7)
1 (4.5)
4 (18.2)
13 (61.9)
2 (10.0)
6 (28.6)
17 (77.3)
2 (9.1)
3 (13.6)
Weight (kg) 71.2 ± 13.6 67.4 ± 12.7 70.8 ± 15.1
Body Mass Index 
(kg/m2)
<18.5
18.5 - <25.0
25.0 - <30.0
≥30.0
25.9 ± 4.2
0
10 (45.5)
6 (27.3)
6 (27.3)
25.3 ± 4.5
2 (9.5)
9 (42.9)
5 (23.8)
5 (23.8)
25.8 ± 4.8
1 (4.5)
12 (54.5)
4 (18.2)
5 (22.7)
Current tobacco use 0 2 (9.5) 0
Data presented as mean ± standard deviation or n (%)
E2 = estradiol; SA = Segesterone Acetate
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Table 2. Spotting and bleeding and bothersome assessment in the first month of using a 
contraceptive vaginal ring releasing estradiol 75 mcg, 100 mcg, or 200 mcg per day and 
segesterone acetate 200 mcg per day
E2 75 mcg/day and
SA 200 mcg/day
n=22
E2 100 mcg/day and
SA 200 mcg/day
n=21
E2 200 mcg/day and
SA 200 mcg/day
n=22
Week 1*ǂ
Spotting
Bothersome
Bleeding
Bothersome
7 (31.8)
0
8 (36.4)
0
3 (14.3)
1 (33.3)
2 (9.5)
0
6 (27.3)
2 (33.3)
6 (27.3)
3 (50.0)
Week 2*
Spotting
Bothersome
Bleeding
Bothersome
4 (18.2)
3 (75.0)
1 (4.5)
1 (100)
5 (23.8)
2 (40.0)
4 (19.0)
4 (100)
1 (4.5)
1 (100)
0
0
Week 3*
Spotting
Bothersome
Bleeding
Bothersome
7 (31.8)
5 (71.4)
4 (18.2)
4 (100)
5 (23.8)
4 (80.0)
4 (19.0)
2 (50.0)
0
0
0
0
Week 4*
Spotting
Bothersome
Bleeding
Bothersome
10 (45.5)
5 (50.0)
7 (31.8)
5 (71.4)
8 (38.1)
7 (87.5)
4 (19.0)
2 (50.0)
0
0
1 (4.5)
1 (100)
*Participants reported bleeding or spotting in week prior. Bothersome assessment done in 
participants who reported spotting or bleeding. 
ǂ Participants initiated ring use during menses so the bleeding and spotting in week 1 include 
residual menses from a cycle prior to treatment.
Data presented as n (%); SA = Segesterone Acetate; E2 = estradiol
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Table 3. Scheduled and unscheduled bleeding and spotting with 2-day and 4-day ring-free intervals in participants using a 
contraceptive vaginal ring releasing estradiol 75 mcg, 100 mcg, or 200 mcg per day and segesterone acetate 200 mcg per day
First 30-day extension Second 30-day extensionRing dose n
Scheduled 
bleeding
Unscheduled 
bleeding
Unscheduled 
spotting
Scheduled 
bleeding
Unscheduled 
bleeding
Unscheduled 
spotting
E2 75 mcg/day and 
SA 200 mcg/day
5 3 (60%) 0* 0 (0-11) 3 (60%) 0 (0-4) 0*
E2 100 mcg/day and 
SA 200 mcg/day
6 4 (67%) 0 (0-7) 0 (0-15) 6 (100%) 0 (0-2) 0.5 (0-1)
2 day 
ring-free 
interval
E2 200 mcg/day and 
SA 200 mcg/day
7 7 (100%) 0 (0-2) 2 (0-16) 7 (100%) 0* 3 (0-19)
E2 75 mcg/day and
SA 200 mcg/day
6 6 (100%) 0 (0-3) 0.5 (0-12) 6 (100%) 0 (0-4) 2.5 (0-6)
E2 100 mcg/day and 
SA 200 mcg/day
6 4 (67%) 0* 0.5 (0-6) 6 (100%) 0 (0-17) 0 (0-1)
4 day 
ring-free 
interval
E2 200 mcg/day and 
SA 200 mcg/day
4 4 (100%) 0*  0 (0-4) 4 (100%) 0* 0 (0-2)
Data presented as n (%) or median (range).
SA= Segesterone Acetate; E2= Estradiol
*No range presented because all participants reported no unscheduled bleeding or spotting
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Table 4. Adverse events with contraceptive vaginal ring use releasing estradiol 75 mcg, 100 mcg, 
or 200 mcg per day and segesterone acetate 200 mcg per day*
E2 75 mcg/day 
and
SA 200 mcg/day 
n=22
E2 100 mcg/day 
and
SA 200 mcg/day 
n=21
E2 200 mcg/day 
and
SA 200 mcg/day 
n=22
Total number of participants 
with at least one AE
18 (81.8) 12 (57.1) 16 (72.7)
Headache 8 (36.4) 4 (19.0) 5 (22.7)
Breast tenderness 1 (4.5) 0 5 (22.7)
Urinary tract infection 2 (9.1) 0 3 (13.6)
Dysmenorrhea 2 (9.1) 1 (4.8) 2 (9.1)
Nausea 2 (9.1) 1 (4.8) 2 (9.1)
Dizziness 2 (9.1) 2 (9.5) 0
Nasopharyngitis 2 (9.1) 1 (4.8) 0
Vaginal odor 2 (9.1) 1 (4.8) 0
Vulvovaginal mycotic infection 2 (9.1) 1 (4.8) 0
Urinary frequency 1 (4.5) 0 2 (9.1)
Affect lability 0 2 (9.5) 1 (4.5)
Abdominal distension 0 0 3 (13.6)
*Only AEs experienced by 3 or more study participants were included in this table
E2 = estradiol; SA = Segesterone acetate; AE = adverse event
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Figure Legends
Figure 1. Subject participation in the main and extension studies of three contraceptive vaginal 
rings releasing estradiol and segesterone acetate 
Figure 2. Median estradiol concentration with use of a contraceptive vaginal ring releasing 
estradiol 75, 100, or 200 mcg/day and segesterone acetate 200 mcg/day.  Serum hormone 
concentrations were not assayed between day 30 and day 88.
26
27
